The stock of Phathom Pharmaceuticals Inc (PHAT) has gone up by 20.58% for the week, with a 148.29% rise in the past month and a 79.28% rise in the past quarter. The volatility ratio for the week is 3.33%, and the volatility levels for the past 30 days are 15.03% for PHAT. The simple moving average for the past 20 days is 59.87% for PHAT’s stock, with a 20.51% simple moving average for the past 200 days.
Is It Worth Investing in Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Right Now?
The 36-month beta value for PHAT is at 0.09. Analysts have varying views on the stock, with 6 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for PHAT is 37.85M, and currently, shorts hold a 29.01% of that float. The average trading volume for PHAT on June 20, 2025 was 2.71M shares.
PHAT) stock’s latest price update
Phathom Pharmaceuticals Inc (NASDAQ: PHAT)’s stock price has gone rise by 3.81 in comparison to its previous close of 10.50, however, the company has experienced a 20.58% increase in its stock price over the last five trading days. globenewswire.com reported 2025-06-16 that FLORHAM PARK, N.J., June 16, 2025 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that the U.S. Food and Drug Administration (FDA) has updated the Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”) to accurately reflect the full 10-year period of non-patent New Chemical Entity (NCE) exclusivity for VOQUEZNA® (vonoprazan) 10 mg and 20 mg tablets.
Analysts’ Opinion of PHAT
Many brokerage firms have already submitted their reports for PHAT stocks, with Cantor Fitzgerald repeating the rating for PHAT by listing it as a “Overweight.” The predicted price for PHAT in the upcoming period, according to Cantor Fitzgerald is $23 based on the research report published on February 14, 2025 of the current year 2025.
Stifel, on the other hand, stated in their research note that they expect to see PHAT reach a price target of $24. The rating they have provided for PHAT stocks is “Buy” according to the report published on May 03rd, 2024.
Needham gave a rating of “Buy” to PHAT, setting the target price at $26 in the report published on January 05th of the previous year.
PHAT Trading at 118.38% from the 50-Day Moving Average
After a stumble in the market that brought PHAT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -44.70% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PHAT starting from Topper James N, who purchase 3,780 shares at the price of $3.86 back on May 21 ’25. After this action, Topper James N now owns 59,403 shares of Phathom Pharmaceuticals Inc, valued at $14,609 using the latest closing price.
Topper James N, the Director of Phathom Pharmaceuticals Inc, purchase 6,300 shares at $3.32 during a trade that took place back on May 14 ’25, which means that Topper James N is holding 55,623 shares at $20,919 based on the most recent closing price.
Stock Fundamentals for PHAT
Current profitability levels for the company are sitting at:
- -3.5 for the present operating margin
- 0.86 for the gross margin
The net margin for Phathom Pharmaceuticals Inc stands at -3.07. The total capital return value is set at -1.3.
Based on Phathom Pharmaceuticals Inc (PHAT), the company’s capital structure generated -1.51 points at debt to capital in total, while cash flow to debt ratio is standing at -1.39. The debt to equity ratio resting at -0.6. The interest coverage ratio of the stock is -3.93.
Currently, EBITDA for the company is -261.52 million with net debt to EBITDA at 0.03. When we switch over and look at the enterprise to sales, we see a ratio of 9.19. The receivables turnover for the company is 2.25for trailing twelve months and the total asset turnover is 0.28. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.58.
Conclusion
In conclusion, Phathom Pharmaceuticals Inc (PHAT) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
